Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
NCT00364780 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sensitivity to EGFR inhibitors has been linked to specific EGFR mutations and associated with certain clinical characteristics in patients with NSCLC (eg, female, minimal and remote smoking history, and adenocarcinoma histology).
Conditions Studied
Interventions
- DRUG XL647
Study Locations (7)
Illinois
- University of Chicago — Chicago
- Carle Cancer Center — Urbana
Florida
- Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie
Massachusetts
- Massachusetts General Hospital — Boston
Michigan
- Wayne University, Wertz Clinical Cancer Center, Karmanos Center — Detroit
New York
- Memorial Sloan Kettering Cancer Center — New York
Ohio
- Case Western Reserve University, University Hospitals of Cleveland — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364780
The ClinicalTrials.gov registry entry for NCT00364780 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Non-small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which XL647 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00364780 reports 7 study locations spanning 6 distinct geographic areas — top geographies include Illinois, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00364780 about?
NCT00364780 is a clinical study titled "Study of XL647 in Subjects With Non-Small-Cell Lung Cancer". The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sen...
What is the current status of trial NCT00364780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-07. Estimated completion is 2010-08.
What conditions does trial NCT00364780 study?
This clinical trial studies the following conditions: Non-small-cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00364780?
The interventions under investigation include: XL647 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00364780?
This trial is sponsored by Kadmon Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00364780 being conducted?
This trial has 7 study locations across Florida, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.